Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

bioAffinity Technologies, Inc.

NASDAQ: BIAF · Industrial Applications and Services · 12 alerts · CIK 1712762

Share price
$2.00Close, Nov 16
Market cap
$3.64M
Shares outstanding
1.82MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All bioAffinity Technologies, Inc. filings on SEC EDGAR ↗

9:30 AM ET 8-K
Clinical Trial Data

bioAffinity Technologies Clinical Trial Data

bioAffinity Technologies announced it will present positive research data at the CHEST 2026 annual meeting regarding its CyPath Lung test and a new investigational test for asthma and COPD-related lung inflammation. The presentation will focus on improving lung cancer risk stratification and managing pulmonary nodules using the company's noninvasive flow cytometry technology.

Counterparty
American College of Chest Physicians
9:23 AM ET 8-K
Clinical Trial Data

bioAffinity Technologies Clinical Trial Data

bioAffinity Technologies announced it will present positive research data at the CHEST 2026 annual meeting regarding its sputum-based tests for lung inflammation. The data demonstrates the ability to detect multiple protein biomarkers and biologic drug targets for asthma and COPD using the company's flow cytometry and AI platform. The research aims to support a precision medicine approach for identifying patients who could benefit from specific biologic therapies.

Counterparty
American College of Chest Physicians
4:31 PM ET 8-K
Capital Raise

bioAffinity Technologies Capital Raise of $4M

bioAffinity Technologies entered into a securities purchase agreement with an institutional investor to raise approximately $4 million in gross proceeds. The offering consists of 116,545 shares of common stock and pre-funded warrants for 536,836 shares, priced at $6.122 and $6.115 respectively, alongside a private placement of unregistered warrants.

Value
$4M
Counterparty
institutional investor
8:32 AM ET 8-K
Clinical Trial Data

bioAffinity Technologies Clinical Trial Data

bioAffinity Technologies is presenting clinical data and research updates for its CyPath Lung diagnostic at the 2026 NAVREF Annual Conference. The presentations include clinical case studies demonstrating how the test prevents unnecessary invasive procedures and an update on the 2,000-patient FlowPath Lung longitudinal study involving veterans and military personnel.

Counterparty
National Association of Veterans’ Research and Education Foundations (NAVREF)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.